While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...

Novo Nordisk might be down but it's not out of the weight-loss drug race. The Danish maker of blockbuster drug Wegovy has had ...

Patients on daily pill lost about 17% of body weight in trial Results nearly identical to injectable Wegovy New obesity pill ...

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study ...

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity ...

Novo Nordisk ( NVO 6.38%) -- the original Ozempic stock -- jumped higher again Thursday after announcing results from a ...

"That's an easy move to make out of the gate, but it's also unusual at Novo, and it's piqued investor interest," said ...

Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.

Novo Nordisk’s injectable amylin alternative to Wegovy appears to have underperformed the approved obesity blockbuster in a ...

The company, which is also known for its Ozempic diabetes treatment, already said in August that it had implemented a ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...